{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2"},{"groupId":"OG001","value":"16.9"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG002","lowerLimit":"33.4","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG003","lowerLimit":"7.6","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG004","lowerLimit":"2.2","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG005","lowerLimit":"1.1","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG006","lowerLimit":"0.6","upperLimit":"NA","value":"5.0"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG007","lowerLimit":"1.1","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG008","lowerLimit":"0.5","upperLimit":"NA","value":"11.8"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"43"},{"groupId":"OG010","value":"45"}],"units":"Participants"}],"description":"OS was defined as the time from the date of first dose, or date of randomization for participants in the Expansion Part B, to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"OG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.","id":"OG006","title":"R/R AML Dose Escalation: GEN3014 Dose Level 1"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG007","title":"RRMM Expansion Part A: GEN3014"},{"description":"Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG008","title":"R/R DLBCL Expansion Part A: GEN3014"},{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG009","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG010","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"MEDIAN","populationDescription":"Full Analysis set=all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed=participants evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Dose Escalation, Expansion Part A and Expansion Part B: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}